[A25-112] Tisotumab vedotin (cervical cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 01.12.2025
Project no.:
A25-112
Commission:
Commission awarded on 29.08.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with recurrent or metastatic cervical cancer
Result of dossier assessment:
- Patients with disease progression during or after platinum-based first-line chemotherapy who have not been pretreated with a PD-(L)1 antibody and for whom further antineoplastic therapy is an option: added benefit not proven
- Patients with disease progression during or after platinum-free first-line chemotherapy without a PD-(L)1 antibody or first-line combination therapy consisting of chemotherapy and a PD-(L)1 antibody or sequential therapy with platinum-containing chemotherapy and a PD-(L)1 antibody and for whom further antineoplastic therapy is an option: added benefit not proven
- Patients with disease progression during or after prior systemic therapy for whom further antineoplastic therapy is not an option: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-112